| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PRCT | Common Stock | Other | $0 | -1.95M | -73.26% | $0.00 | 712K | May 20, 2024 | By White Tailed Ptarmigan, LP | F1, F2 |
| transaction | PRCT | Common Stock | Other | $0 | -164K | -47.61% | $0.00 | 181K | May 20, 2024 | By Mallard Fund, L.P. | F1, F3 |
| holding | PRCT | Common Stock | 66.3K | May 20, 2024 | By Kestrel Fund, L.P. | F1, F4 | |||||
| holding | PRCT | Common Stock | 367K | May 20, 2024 | By The 2:22 DNA Trust | F4, F6 | |||||
| holding | PRCT | Common Stock | 57.8K | May 20, 2024 | Direct | F4, F5 |
| Id | Content |
|---|---|
| F1 | CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein. |
| F2 | On May 20, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 163,030 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. |
| F3 | On May 20, 2024, Mallard Fund, L.P. distributed shares on a pro rata basis, for no consideration, including 37 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13. |
| F4 | Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on May 20 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. |
| F5 | Includes shares previously held indirectly through Mallard Fund, L.P., which were distributed on a pro rata basis, for no consideration, on May 20, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13. |
| F6 | Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by The 2:22 DNA Trust except to the extent of any pecuniary interest therein. |